New COVID-19 Vaccine Candidate Uses Existing Deactivated Rabies Vaccine as Vehicle for Coronavirus Proteins
By HospiMedica International staff writers Posted on 21 May 2020 |
Image: New COVID-19 Vaccine Candidate Uses Existing Deactivated Rabies Vaccine as Vehicle for Coronavirus Proteins (Photo courtesy of Thomas Jefferson University)
Thomas Jefferson University (Philadelphia, PA, USA) has signed an exclusive deal with vaccine innovator Bharat Biotech International (Hyderabad, India) to develop a new vaccine candidate for COVID-19 invented at Jefferson.
Under the license agreement, Bharat Biotech gains exclusive rights to develop, market and deliver Jefferson’s vaccine across the world excluding countries such as US, Europe, Japan etc., where Jefferson continues to seek partners. With support from the Department of Biotechnology, Govt. of India, Bharat Biotech aims to get into human trials as soon as December 2020.
Of the 90 or so coronavirus vaccines in development, about 25% use an established vaccine to act as a “carrier” or vector for the target virus, in this case, the coronavirus SARS-COV-2 spike protein. Not every vaccine produces the same level of the immune response. The vector used in this new vaccine is a deactivated rabies vaccine that is known to generate a rigorous but safe immune reaction that confers life-long protection, and has been proven safe for all populations, including children and pregnant women. The vaccine developed in January this year recently completed preliminary tests in animal models and showed a strong antibody response in mice receiving the vaccine. The researchers are currently testing whether vaccinated animals are protected from SARS-CoV-2 infection with results expected in June.
“We are leveraging the properties of a very effective vaccine – one that provides life-long immunity against one of the biggest global threats of our time,” said Dr. Mark Tykocinski MD, Provost and Executive Vice President for Academic Affairs of Thomas Jefferson University, and Dean of its Sidney Kimmel Medical College. “Rather than go with an untested approach, we have a leg-up by using a vaccine that is safe, effective, and exceptionally good at creating a strong immune response – which is something not every vaccine can do.”
“Our partnership with Bharat Biotech will accelerate our vaccine candidate through the next phases of development,” said Infectious Diseases expert Professor Matthias Schnell who directs The Jefferson Vaccine Institute and chairs Jefferson’s Department of Microbiology and Immunology. “We will be able to complete animal testing and move to phase 1 clinical trial rapidly.”
“In view of the imminent demand for an effective vaccine, Bharat Biotech is pleased to collaborate with Thomas Jefferson, USA towards developing a new vaccine for COVID-19 using an inactivated rabies vector platform,” said Dr. Krishna Mohan, Chief Executive Officer of Bharat Biotech. “We are particularly excited about this technology since the basic proof of concept has been established while using it for other pandemic infectious diseases. Bharat Biotech is committed to global public health and will be involved in an end to end development of the vaccine including comprehensive clinical trials to achieve commercial licensure.”
Related Links:
Thomas Jefferson University
Bharat Biotech International
Under the license agreement, Bharat Biotech gains exclusive rights to develop, market and deliver Jefferson’s vaccine across the world excluding countries such as US, Europe, Japan etc., where Jefferson continues to seek partners. With support from the Department of Biotechnology, Govt. of India, Bharat Biotech aims to get into human trials as soon as December 2020.
Of the 90 or so coronavirus vaccines in development, about 25% use an established vaccine to act as a “carrier” or vector for the target virus, in this case, the coronavirus SARS-COV-2 spike protein. Not every vaccine produces the same level of the immune response. The vector used in this new vaccine is a deactivated rabies vaccine that is known to generate a rigorous but safe immune reaction that confers life-long protection, and has been proven safe for all populations, including children and pregnant women. The vaccine developed in January this year recently completed preliminary tests in animal models and showed a strong antibody response in mice receiving the vaccine. The researchers are currently testing whether vaccinated animals are protected from SARS-CoV-2 infection with results expected in June.
“We are leveraging the properties of a very effective vaccine – one that provides life-long immunity against one of the biggest global threats of our time,” said Dr. Mark Tykocinski MD, Provost and Executive Vice President for Academic Affairs of Thomas Jefferson University, and Dean of its Sidney Kimmel Medical College. “Rather than go with an untested approach, we have a leg-up by using a vaccine that is safe, effective, and exceptionally good at creating a strong immune response – which is something not every vaccine can do.”
“Our partnership with Bharat Biotech will accelerate our vaccine candidate through the next phases of development,” said Infectious Diseases expert Professor Matthias Schnell who directs The Jefferson Vaccine Institute and chairs Jefferson’s Department of Microbiology and Immunology. “We will be able to complete animal testing and move to phase 1 clinical trial rapidly.”
“In view of the imminent demand for an effective vaccine, Bharat Biotech is pleased to collaborate with Thomas Jefferson, USA towards developing a new vaccine for COVID-19 using an inactivated rabies vector platform,” said Dr. Krishna Mohan, Chief Executive Officer of Bharat Biotech. “We are particularly excited about this technology since the basic proof of concept has been established while using it for other pandemic infectious diseases. Bharat Biotech is committed to global public health and will be involved in an end to end development of the vaccine including comprehensive clinical trials to achieve commercial licensure.”
Related Links:
Thomas Jefferson University
Bharat Biotech International
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans